PU.1 Promotes Monocyte Development in Part By Transcriptionally Activating c-Fos, Egr-1 and Egr-2

PU.1 is an Ets family transcription factor with multiple roles in hematopoiesis. In addition to its critical involvement in regulating the function of hematopoietic stem cells, PU.1 has been shown to regulate myeloid and lymphoid development in a graded manner with high levels of PU.1 favoring monocyte development and low expression levels inducing B cell fate. The molecular mechanism by which PU.1 promotes monocyte development remains incompletely understood. We show here that in murine myeloid 32D and PUER cells, and lineage negative (Lin-) bone marrow (BM) cells expressing PUER protein in which PU.1 was fused to the estrogen receptor ligand binding domains, treatment with 4-hydroxytamoxifen (4-HT), which activated PU.1, augmented the expression of c-Fos, Egr-1 and Egr-2. In contrast, PU.1 knockdown using shRNAs reduced c-Fos, Egr-1 and Egr-2 expression. c-Fos, Egr-1 and Egr-2 are the immediate early response genes of the Erk1/2 pathway and have been shown to promote monocyte development. A PU.1 mutant defective in c-Jun interaction failed to augment c-Fos, Egr-1 and Egr-2 expression, indicating that PU.1-mediated upregulation of c-Fos, Egr-1 and Egr-2 was dependent on its interaction with c-Jun. Using ChIP and luciferase reporter assays, we further demonstrate that PU.1 transcriptionally activated c-Fos, Egr-1 and Egr-2 through directly binding to their promoters. Activation of PU.1 with 4-HT in 32D, PUER and Lin- BM cells induced monocyte development. Notably, shRNA-mediated knockdown of c-Fos or Egr-1 resulted in a shift in the development from monocytes to neutrophils in response to PU.1 activation. Knockdown of c-Fos and Egr-1 also affected the expression of other myeloid-specific transcription factors, including C/EBPα and Gfi1. PU.1-induced upregulation of c-Fos, Egr-1 and Egr-2 in PUER cells was abolished upon inhibition of Erk1/2 signaling with the Mek1/2 inhibitors U0126 or PD032901. Interestingly, treatment of PUER cells with either Mek1/2 inhibitor redirected PUER cells to develop along the neutrophil lineage at the expense of monocyte fate in response to PU.1 activation. Together, these results reveal an important mechanism by which PU.1 promotes monocyte development, i.e., through transcriptional activation of c-Fos, Egr-1, and Egr-2.

Authors

Institutions

Publication Details

Journal
Blood
Published
2024-11-05
DOI
https://doi.org/10.1182/blood-2024-203383
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PU.1 Promotes Monocyte Development in Part By Transcriptionally Activating c-Fos, Egr-1 and Egr-2

Hamid Bashir, G C Binod, Fan Dong
Blood
Immune cells in cancer
article

PU.1 Promotes Monocyte Development in Part By Transcriptionally Activating c-Fos, Egr-1 and Egr-2

Hamid Bashir, G C Binod, Fan Dong
article en

Abstract

PU.1 is an Ets family transcription factor with multiple roles in hematopoiesis. In addition to its critical involvement in regulating the function of hematopoietic stem cells, PU.1 has been shown to regulate myeloid and lymphoid development in a graded manner with high levels of PU.1 favoring monocyte development and low expression levels inducing B cell fate. The molecular mechanism by which PU.1 promotes monocyte development remains incompletely understood. We show here that in murine myeloid 32D and PUER cells, and lineage negative (Lin-) bone marrow (BM) cells expressing PUER protein in which PU.1 was fused to the estrogen receptor ligand binding domains, treatment with 4-hydroxytamoxifen (4-HT), which activated PU.1, augmented the expression of c-Fos, Egr-1 and Egr-2. In contrast, PU.1 knockdown using shRNAs reduced c-Fos, Egr-1 and Egr-2 expression. c-Fos, Egr-1 and Egr-2 are the immediate early response genes of the Erk1/2 pathway and have been shown to promote monocyte development. A PU.1 mutant defective in c-Jun interaction failed to augment c-Fos, Egr-1 and Egr-2 expression, indicating that PU.1-mediated upregulation of c-Fos, Egr-1 and Egr-2 was dependent on its interaction with c-Jun. Using ChIP and luciferase reporter assays, we further demonstrate that PU.1 transcriptionally activated c-Fos, Egr-1 and Egr-2 through directly binding to their promoters. Activation of PU.1 with 4-HT in 32D, PUER and Lin- BM cells induced monocyte development. Notably, shRNA-mediated knockdown of c-Fos or Egr-1 resulted in a shift in the development from monocytes to neutrophils in response to PU.1 activation. Knockdown of c-Fos and Egr-1 also affected the expression of other myeloid-specific transcription factors, including C/EBPα and Gfi1. PU.1-induced upregulation of c-Fos, Egr-1 and Egr-2 in PUER cells was abolished upon inhibition of Erk1/2 signaling with the Mek1/2 inhibitors U0126 or PD032901. Interestingly, treatment of PUER cells with either Mek1/2 inhibitor redirected PUER cells to develop along the neutrophil lineage at the expense of monocyte fate in response to PU.1 activation. Together, these results reveal an important mechanism by which PU.1 promotes monocyte development, i.e., through transcriptional activation of c-Fos, Egr-1, and Egr-2.

BloodVol. 144(Supplement 1)
University of Toledo (US)
Openalex Percentile: Top 71%
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.